Johnson & Johnson's RYBREVANT plus chemotherapy shows longest reported median overall survival in specific lung cancer

Johnson & Johnson announced that its treatment RYBREVANT (amivantamab-vmjw), when used alongside chemotherapy, has achieved the longest reported median overall survival for patients diagnosed with EGFR exon 20 insertion mutation-positive lung cancer. This outcome represents a notable advancement for a patient group that has historically faced limited treatment options and a low five-year survival rate, reported at approximately 8%.

The findings, presented in Seoul, South Korea, highlight the combination therapy's differentiated approach. The treatment targets both EGFR and MET pathways simultaneously, which has led to a durable benefit for patients. This dual-targeting strategy is significant because EGFR exon 20 insertion mutations are a rare but aggressive form of lung cancer often resistant to standard EGFR inhibitors.

RYBREVANT's ability to address these specific mutations offers a new therapeutic avenue for individuals with few alternative treatments. The development signifies a step forward in managing this challenging subset of non-small cell lung cancer.

Johnson & Johnson plans to continue its research efforts to further evaluate RYBREVANT's role in lung cancer treatment and improve patient prognoses.